Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6588272 | 0.79 | KMT2A (0.50) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 | |
| SCHEMBL6007696 | 0.79 | KMT2A (0.50) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 | |
| SCHEMBL6007689 | 0.79 | KMT2A (0.50) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6007647 | 0.78 | KMT2A (0.49) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6007653 | 0.78 | KMT2A (0.49) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 | |
| SCHEMBL13059438 | 0.76 | KMT2A (0.68) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 | |
| SCHEMBL28263863 | 0.75 | KMT2A (0.63) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 | |
| SCHEMBL7333685 | 0.74 | KMT2A (0.65) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 | |
| SCHEMBL9212186 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9AMAPTROCK2 | |
| SCHEMBL14996180 | 0.73 | KMT2A (0.67) | SMN1; SMN2RAB9AKMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | claimed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | claimed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| EP-2066632-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | Chong Kun Dang Pharmaceutical Corp. (KR) | 2009-06-10 | — | — | EP | claimed |
| WO-2008038955-A1 | BENZOPHENONE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2008-04-03 | — | — | WO | claimed |
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176798-A1 | New compounds III | GPR119, FABP4, GLP1R | SMN1; SMN2 4732/4885RAB9A 4294/4885KMT2A 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.